- Home
- NVCR
NVCR
NovoCure Limited
as of 08-10-2026 12:42pm EST
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
| Founded: | 2000 | Country: | Switzerland |
| Employees: | N/A | City: | ST. HELIER |
| Market Cap: | 2.0B | IPO Year: | 2015 |
| Target Price: | $28.08 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.75 | EPS Growth: | 21.79 |
| 52 Week Low/High: | $9.82 - $21.45 | Next Earning Date: | 04-30-2026 |
| Revenue: | $655,353,000 | Revenue Growth: | 8.28% |
| Revenue Growth (this year): | 7.72% | Revenue Growth (next year): | 6.74% |
| P/E Ratio: | -21.85 | Index: | N/A |
| Free Cash Flow: | -75679000.0 | FCF Growth: | N/A |
AI-Powered NVCR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of NovoCure Limited (NVCR)
Chief Executive Officer
Avg Cost/Share
$17.93
Shares
34,273
Total Value
$614,634.85
Owned After
459,520
SEC Form 4
Director
Avg Cost/Share
$15.77
Shares
2,945
Total Value
$46,444.71
Owned After
14,288
SEC Form 4
Director
Avg Cost/Share
$15.77
Shares
2,945
Total Value
$46,444.71
Owned After
11,324
SEC Form 4
Director
Avg Cost/Share
$15.77
Shares
2,945
Total Value
$46,444.71
Owned After
20,465
SEC Form 4
Director
Avg Cost/Share
$15.77
Shares
2,945
Total Value
$46,444.71
Owned After
197,657
SEC Form 4
Director
Avg Cost/Share
$15.77
Shares
2,945
Total Value
$46,444.71
Owned After
13,861
SEC Form 4
Director
Avg Cost/Share
$15.77
Shares
2,945
Total Value
$46,444.71
Owned After
11,324
SEC Form 4
Director
Avg Cost/Share
$15.77
Shares
2,945
Total Value
$46,444.71
Owned After
89,499
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Leonard Frank X | NVCR | Chief Executive Officer | Jun 4, 2026 | Sell | $17.93 | 34,273 | $614,634.85 | 459,520 | |
| Scannell Timothy J | NVCR | Director | Jun 2, 2026 | Sell | $15.77 | 2,945 | $46,444.71 | 14,288 | |
| Ocean Allyson J | NVCR | Director | Jun 2, 2026 | Sell | $15.77 | 2,945 | $46,444.71 | 11,324 | |
| Hung David | NVCR | Director | Jun 2, 2026 | Sell | $15.77 | 2,945 | $46,444.71 | 20,465 | |
| VERNON W ANTHONY | NVCR | Director | Jun 2, 2026 | Sell | $15.77 | 2,945 | $46,444.71 | 197,657 | |
| HILLEMAN JERYL L | NVCR | Director | Jun 2, 2026 | Sell | $15.77 | 2,945 | $46,444.71 | 13,861 | |
| Stafford Kristin | NVCR | Director | Jun 2, 2026 | Sell | $15.77 | 2,945 | $46,444.71 | 11,324 | |
| LEUNG GABRIEL | NVCR | Director | Jun 2, 2026 | Sell | $15.77 | 2,945 | $46,444.71 | 89,499 |
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K BUY Jul 23, 2026 · 100% conf.
Q2 2026 Earnings
8-K BUYJul 23, 2026 · 100% conf.
1D
-0.20%
$19.56
Act: -9.95%
5D
+7.13%
$21.00
20D
+0.61%
$19.72
nvcr-20260723
0001645113false00016451132026-07-012026-07-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
July 23, 2026
Date of Report (date of earliest event reported)
NovoCure Limited
(Exact name of registrant as specified in its charter)
Jersey 001-37565 98-1057807
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
No. 4 The Forum, Grenville Street
St. Helier
Jersey
JE2 4UF
(Address of Principal Executive Offices)
(Zip Code)
+44 (0) 15 3475 6700
Registrant's telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Ordinary Shares, no par valueNVCRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 2.02 Results of Operations and Financial Condition.
On July 23, 2026, the Company issued a press release announcing certain financial results for the quarter ended
June 30, 2026. A copy of the press release is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1 Press Release of NovoCure Limited, dated July 23, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NovoCure Limited
(Registrant)
Date: July 23, 2026
By: /s/ Christoph Brackmann
Name: Christoph Brackmann
Title: Chief Financial Officer
2026 Q1 Q1 2026 Earnings
8-K BUY Apr 30, 2026 · 100% conf.
Q1 2026 Earnings
8-K BUYApr 30, 2026 · 100% conf.
1D
-2.54%
$14.81
Act: +9.14%
5D
+6.23%
$16.15
Act: +10.72%
20D
-2.18%
$14.87
Act: +11.78%
nvcr-20260430
0001645113false00016451132026-04-012026-05-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
April 30, 2026
Date of Report (date of earliest event reported)
NovoCure Limited
(Exact name of registrant as specified in its charter)
Jersey 001-37565 98-1057807
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
No. 4 The Forum, Grenville Street
St. Helier
Jersey
JE2 4UF
(Address of Principal Executive Offices)
(Zip Code)
+44 (0) 15 3475 6700
Registrant's telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Ordinary Shares, no par valueNVCRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 2.02 Results of Operations and Financial Condition.
On April 30, 2026, the Company issued a press release announcing certain financial results for the quarter ended
March 31, 2026. A copy of the press release is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1 Press Release of NovoCure Limited, dated April 30, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NovoCure Limited
(Registrant)
Date: April 30, 2026
By: /s/ Christoph Brackmann
Name: Christoph Brackmann
Title: Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
1D
-2.44%
$13.41
Act: -0.58%
5D
-6.57%
$12.85
Act: +3.49%
20D
-10.02%
$12.37
nvcr-202602260001645113false00016451132026-02-012026-02-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
February 26, 2026 Date of Report (date of earliest event reported)
NovoCure Limited (Exact name of registrant as specified in its charter)
Jersey 001-3756598-1057807
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
No. 4 The Forum, Grenville Street St. Helier Jersey
JE2 4UF
(Address of Principal Executive Offices) (Zip Code)
+44 (0) 15 3475 6700 Registrant's telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Ordinary Shares, no par valueNVCRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On February 26, 2026, the Company issued a press release announcing certain financial results for the fiscal year and quarter ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1Press Release of NovoCure Limited, dated February 26, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NovoCure Limited (Registrant)
Date: February 26, 2026
By: /s/ Christoph Brackmann Name: Christoph Brackmann Title: Chief Financial Officer
Compare NVCR vs Leading Stocks
See how NVCR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NVCR NovoCure Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.